TD,
I think Leo is NOT in the business of uplisting prior to some definitive results (B p2b, or K actual data). Since he knows both of those are right around the corner he is waiting to give us results and uplisting as a coordinated event... think ASM (1st qtr 2015?).
Leo is at the controls and knows these waters well.
Recall his comment from 2012 R&R regarding Kevetrin:
Two quotes from Leo's presentation at Rodman 9/11/12:
1. "Kevetrin is thoroughly protected through pending patents which cover tens of thousands of possible future chemical combinations for new drugs, a potentially very valuable proposition for multiple drug developments in the future."
2. ". I’m convinced beyond a doubt if we are able to see in the clinical trials even a portion of the results that we’ve seen in the lab studies, Cellceutix will experience a wave of unprecedented growth. "
Add to that his recent comments on B and I don't see how the current lack of uplisting is of concern.
I believe CTIX has already seen more than a "portion" of the K lab results.....
Go CTIX!